08:44 AM EST, 12/12/2024 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Thursday said that its Mexican affiliate received regulatory approval for Tavalisse, for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Thrombocytopenia is a platelet disorder where the platelet count is too low.

Tavalisse, or fostamatinib disodium hexahydrate, is expected to be launched in Mexico in the first half of 2026.